이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

만성 폐쇄성 폐질환에 대한 병원 전 표준 대 표적 산소 요법 (STOP-COPD)

2026년 9월 30일 업데이트: Central Denmark Region

The STOP-COPD trial is a randomized, patient-blinded, prehospital clinical trial designed to evaluate the effect of titrated oxygen therapy compared to standard oxygen treatment in patients with suspected acute exacerbation of chronic obstructive pulmonary disease (AECOPD) treated with inhaled bronchodilators. The primary objective is to determine whether a titrated oxygen strategy targeting SpO₂ 88-92% can reduce 30-day mortality compared to the current standard practice using 100% compressed oxygen as a nebulizer driver.

연구 개요

상세 설명

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. In the prehospital setting, patients with suspected acute exacerbation of COPD (AECOPD) are frequently treated with inhaled bronchodilators driven by 100% oxygen, despite concerns that high-concentration oxygen therapy may worsen hypercapnia and acidosis, leading to increased mortality.

The STOP-COPD trial is a prospective, randomized, parallel-group, superiority trial conducted in the Prehospital Emergency Medical Services, Central Denmark Region. Patients aged 40 years or older with suspected AECOPD requiring inhaled bronchodilators are randomized 1:1 to receive either:

Titrated oxygen therapy: Inhaled bronchodilators driven by compressed air with supplemental oxygen titrated to maintain SpO₂ 88-92%.

Standard treatment: Inhaled bronchodilators driven by 100% compressed oxygen according to standard protocols.

The primary outcome is 30-day all-cause mortality. Secondary outcomes include 24-hour and 7-day mortality, need for invasive or non-invasive ventilation, development of respiratory acidosis upon hospital arrival, ICU admission rate, length of hospital and ICU stay, patient-experienced dyspnoea, and readmission rates. A total of 1,888 patients will be enrolled.

The study is conducted under emergency research regulations allowing enrolment before informed consent, with consent obtained as soon as feasible after hospital admission. This trial seeks to evaluate whether titrating oxygen delivery in the prehospital phase can improve survival and clinical outcomes for patients with AECOPD.

연구 유형

중재적

등록 (추정된)

1888

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Martin F Gude, PhD
  • 전화번호: 0045 25343621
  • 이메일: martgude@rm.dk

연구 연락처 백업

  • 이름: Arne Sylvester R Jensen
  • 전화번호: 22396968
  • 이메일: arjens@rm.dk

연구 장소

      • Aarhus N, 덴마크, 8200
        • 모병
        • Prehospital Emergency Medical Servises, Central Denmark Region

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

40년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Patients over the age of 40
  • EMT or Paramedic suspected AECOPD
  • Confirmed suspicion of COPD

Exclusion Criteria:

  • Bronchospasm due to asthma, allergic reaction or non-COPD conditions
  • Known or suspected pregnancy
  • Prehospital Non-invasive, invasive or assisted bag mask ventilation
  • Allergy to inhaled bronchodilators (Salbutamol)
  • Inter-hospital transfer
  • More than 2 doses (5 mg salbutamol) inhalation drug, acute treatment by EMS (emergency medical service) personnel, before allocated treatment is initiated
  • Suspicion of acute coronary syndrome

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Titrated Oxygen

If the treating EMT or paramedic finds indications for inhaled bronchodilators, this will be done with compressed air 6-8 l/min. as the driver for the nebulizer. The patient will have a Bi-nasal EtCO2 (end-tidal carbon dioxide) meter placed under the nebulizer. This will measure the EtCO2 during the treatment and at the same time oxygen can be titrated through this to a target SpO2 of 88-92%. Repeated treatment will be at the discretion of the treating EMT or paramedic according to SOP (standard operating procedures).

Following scenarios regarding SpO2 can occur during treatment:

SpO2 <88%: Supplemental oxygen via the EtCO2-meter up to 10 l/min, if higher oxygen levels are needed oxygen will be used as driver for the nebulizer. If the SpO2 remains under 88% additional oxygen can be added via the EtCO2-meter.

SpO2 88-92%: No intervention.

SpO2 >92%: No intervention.

If repeated treatment is not indicated the patient receives oxygen to SpO2 88-92% according SOP.

Titrated oxygen strategy - a mix of supplemental oxygen and compressed atmospheric air as driver for inhaled bronchodilators to target SpO2 88-92%

다른 이름들:
  • 분무기 드라이버로서 Spo₂ 88-92% 및 압축 대기 공기에 대한 산소 적정
활성 비교기: Standard Oxygen

If the treating EMT or paramedic finds indication for inhaled bronchodilators, this will be done with oxygen 6-8 l/min. as the driver for the nebulizer. The patient will have a Bi-nasal EtCO2 meter placed under the nebulizer. This will measure the EtCO2 during the treatment and at the same time mask the patient for group allocation. Repeated treatment will be at the discretion of the treating EMT or paramedic according to SOP.

Following scenarios regarding SpO2 can occur during treatment:

SpO2 <88%: Supplemental oxygen via the EtCO2 -meter up to 10 l/min.

SpO2 88-92%: No intervention.

SpO2 >92%: No intervention.

If repeated treatment is not indicated the patient receives oxygen to SpO2 88-92% according SOP.

Standard care using compressed oxygen (100%) as driver for inhaled bronchodilators

다른 이름들:
  • 분무기 드라이버로서 Spo₂ 표적 제한 및 100% 압축 산소가 없음

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Mortality, 30-day
기간: Day 30 from randomization

Vital status assessed 30 days after randomization using hospital electronic medical records

Day 30 from randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Mortality, 24-hour
기간: 24 hours from randomization

Vital status assessed 24 hours after randomization using hospital electronic medical records

24 hours from randomization
Mortality, 7-day
기간: Day 7 from randomization

Vital status assessed 7 days after randomization using hospital electronic medical records

Day 7 from randomization
Length of hospital stay
기간: Day 30 from randomization

Number of days from hospital admission to hospital discharge, collected from hospital electronic medical records

Day 30 from randomization
ICU admission rate
기간: Day 30 from randomization

Proportion of patients admitted to an intensive care unit during the index hospitalization, collected from the electronic hospital medical record

Day 30 from randomization
Length of ICU stay
기간: Day 30 from randomization

Number of days spent in the intensive care unit during the index hospitalization, collected from the patient's electronic hospital medical record

Day 30 from randomization
In-hospital need for NIV (non-invasive ventilation) within 24 hours
기간: Day 30 from randomization

Use of non-invasive ventilation recorded within 24 hours of hospital admission, collected from the patient's electronic hospital medical record

Day 30 from randomization
In-hospital need for NIV within 7 days
기간: Day 30 from randomization

Use of non-invasive ventilation recorded within 7 days of hospital admission, collected from the patient's electronic hospital medical record

Day 30 from randomization
In-hospital need for NIV within 30 days
기간: Day 30 from randomization

Use of non-invasive ventilation recorded within 30 days of randomization, collected from the patient's electronic hospital medical record

Day 30 from randomization
Time to NIV
기간: Day 30 from randomization

Time from hospital admission to initiation of non-invasive ventilation, collected from the patient's electronic hospital medical record

Day 30 from randomization
In-hospital need for invasive mechanical ventilation within 24 hours
기간: Day 30 from randomization

Initiation of invasive mechanical ventilation within 24 hours of hospital admission, collected from the patient's electronic hospital medical record

Day 30 from randomization
In-hospital need for invasive mechanical ventilation within 7 days
기간: Day 30 from randomization

Initiation of invasive mechanical ventilation within 7 days of hospital admission, collected from the patient's electronic hospital medical record

Day 30 from randomization
In-hospital need for invasive mechanical ventilation within 30 days
기간: Day 30 from randomization

Initiation of invasive mechanical ventilation within 30 days of randomization, collected from the patient's electronic hospital medical record

Day 30 from randomization
Time to invasive ventilation
기간: Day 30 from randomization

Time from hospital admission to initiation of invasive mechanical ventilation, collected from the patient's electronic hospital medical record

Day 30 from randomization
Proportion of patients with respiratory acidosis on arrival to hospital
기간: Day 30 from randomization

Presence of respiratory acidosis (PaCO₂ >6.3 kPa and pH <7.35) assessed via arterial blood gas analysis within 30 minutes after arrival, collected from the patient's electronic hospital medical record

Day 30 from randomization
The degree of acidosis based on the pH (potential of hydrogen) value
기간: Day 30 from randomization

Lowest pH value measured from arterial blood gas within 30 minutes of hospital arrival, collected from the patient's electronic hospital medical record

Day 30 from randomization
Patient experienced dyspnoea on a verbal rating scale 0-10
기간: Day 30 from randomization

Patient-reported dyspnoea score at hospital arrival on a scale from 0 (no dyspnoea) to 10 (worst imaginable dyspnoea), collected from the prehospital patient record and hospital medical record

Day 30 from randomization
Readmission rate
기간: Day 30 after discharge

Proportion of patients readmitted to hospital within 30 days after discharge from index hospitalization, collected from the patient's electronic hospital medical record

Day 30 after discharge
Time to readmission
기간: Day 30 after discharge

Number of days from hospital discharge to first hospital readmission within 30 days, collected from the patient's electronic hospital medical record

Day 30 after discharge

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Martin F Gude, PhD, Central Denmark Region

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 6월 2일

기본 완료 (추정된)

2028년 2월 29일

연구 완료 (추정된)

2028년 5월 31일

연구 등록 날짜

최초 제출

2023년 1월 10일

QC 기준을 충족하는 최초 제출

2023년 1월 19일

처음 게시됨 (실제)

2023년 1월 30일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 5925
  • 2022-502003-30-00 (기타 식별자: https://euclinicaltrials.eu)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data (IPD) will be made available to researchers whose proposed use of the data has been approved by the local administration. Data will be shared starting 9 months after publication of the primary results and will be accessible until data are no longer stored, according to current ICMJE recommendations and EU data protection regulations.

All trial-related documents (e.g., protocol, statistical analysis plan) will be made publicly available on the trial website. Patient-related data will not be accessible on the website.

IPD 공유 기간

9 months after primary results publication; data will remain available until de-identified data are no longer stored according to ICMJE recommendations and EU regulations.

IPD 공유 액세스 기준

Researchers must submit a methodologically sound proposal for use of the data. Access will be granted following review and approval by the local trial administration. A data-sharing agreement will be required.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF
  • ANALYTIC_CODE
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다